跳至主要内容
临床试验/NCT01825551
NCT01825551已完成2 期

The Effect of Granulocyte Colony Stimulating Factor (GCSF) in the Treatment of Amyotrophic Lateral Sclerosis (ALS) Patients Referred to Tehran Imam Khomeini and Shariati Hospital Centers in 2013

Tehran University of Medical Sciences1 个研究点 分布在 1 个国家目标入组 40 人开始时间: 2012年11月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
2 期
状态
已完成
入组人数
40
试验地点
1
主要终点
patient's function

研究概览

简要总结

The aim of this study is to evaluate the effect off Granulocyte Colony Stimulating Factor (GCSF) in the treatment of Amyotrophic Lateral Sclerosis (ALS) patients.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Triple (Participant, Care Provider, Investigator)

入排标准

年龄范围
18 Years 至 85 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • age between 18 and 85
  • definite or probable ALS according to revised El Escorial criteria
  • maximum 2 years from initiation of symptoms to study entry
  • mild to moderate disability according to revised ALS functional rating scale (ALSFRS-r)

排除标准

  • familial ALS
  • pregnancy or lactation
  • myeloproliferative or hematologic disorders
  • active immunological disease
  • liver or renal or heart disease
  • HIV positive
  • significant cognitive disorder
  • hypersensitivity to GCSF

研究组 & 干预措施

Granulocyte Colony Stimulating Factor

Active Comparator

Granulocyte Colony Stimulating Factor 10 microgram/ kg/ day for 5 days subcutaneously

干预措施: Granulocyte Colony Stimulating Factor (Drug)

Placebo

Placebo Comparator

normal saline 0.01 ml/kg/day for 5 days subcutaneously

干预措施: Placebo (Drug)

结局指标

主要结局

patient's function

时间窗: one year

based on revised ALS Functional Rating scale (ALSFRS-r)

次要结局

  • muscle power(1 year)
  • mobilizing bone marrow stem cells(1 year)
  • amplitude of compound muscle action potential in ulnar and peroneal nerve(1 year)
  • quality of life(1 year)

研究者

申办方类型
Other
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验

The Effect of GCSF in the Treatment of ALS Patients | 临床试验